• Explore /
  • Videos & Slides
  • / Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.

Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.

Abstract Video & Slides Poster

Presenter

null

John Raymond Zalcberg, PhD, MBBS

School of Public Health and Preventative Medicine, Monash University, and Alfred Health

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03673501

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 748)

DOI

10.1200/JCO.2024.42.3_suppl.748

Abstract #

748

Poster Bd #

M3

Abstract Disclosures

Similar Videos & Slides

Speaker: Jian Li, D.Phil

Speaker: Michael C. Heinrich, MD, FACP

Speaker: George D. Demetri, MD, FASCO, FACP

Speaker: Michael C. Heinrich, MD, FACP